The session will begin by providing a general overview of the prevalence and epidemiology of nonalcoholic fatty liver disease. Immediately after, a summary of the pathophysiology will be provided so that the audience realizes how metabolic problems associated with obesity are also closely linked to non-alcoholic fatty liver disease. A consideration will be given to genetics. Special attention will be placed to reviewing the importance of liver fibrosis. Recent nomenclature changes from non-alcoholic fatty liver disease to metabolic dysfunction associated liver disease (MASLD) will be addressed. The talk will then transition to analyze the recommended clinical assessment (laboratories, imaging, noninvasive tests, etc.), identification of high-risk patients of liver-related events as well as the differential diagnosis. I will close by focusing on the impact of specific dietary interventions and pharmacotherapy on fatty liver disease.

CME/CE Expiration Date: 4/26/27

*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.